Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication

Jason Taylor, Lucia Vojtech, Ingrid Bahner, Donald B. Kohn, Dorothee Von Laer, David W. Russell, Robert E. Richard

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Gene therapy has the potential to control human immunodeficiency virus (HIV) in patients who do not respond to traditional antiviral therapy. In this study, we tested foamy virus (FV) vectors expressing three anti-HIV transgenes, both individually and in a combination vector. The transgenes tested in this study are RevM10, a dominant negative version of the viral rev protein, Sh1, a short hairpin RNA directed against a conserved overlapping sequence of tat and rev, and membrane-associated C46 (maC46), a membrane-attached peptide that blocks HIV cell entry. FV vectors efficiently transduce hematopoietic stem cells and, unlike lentivirus (LV) vectors, do not share viral proteins with HIV. The titers of the FV vectors described in this study were not affected by anti-HIV transgenes. On a direct comparison of FV vectors expressing the individual transgenes, entry inhibition using the maC46 transgene was found to be the most effective at blocking HIV replication. A clinically relevant FV vector expressing three anti-HIV transgenes effectively blocked HIV infection in primary macrophages derived from transduced, peripheral blood CD34-selected cells and in a cell line used for propagating HIV, CEM×174. These results suggest that there are potential benefits of using FV vectors in HIV gene therapy.

Original languageEnglish (US)
Pages (from-to)46-51
Number of pages6
JournalMolecular Therapy
Volume16
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Spumavirus
Virus Replication
Transgenes
HIV-1
HIV
Viral Proteins
Genetic Therapy
Membranes
rev Gene Products
Virus Internalization
Lentivirus
Conserved Sequence
Virus Diseases
Hematopoietic Stem Cells
Small Interfering RNA
Antiviral Agents

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Taylor, J., Vojtech, L., Bahner, I., Kohn, D. B., Laer, D. V., Russell, D. W., & Richard, R. E. (2008). Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication. Molecular Therapy, 16(1), 46-51. https://doi.org/10.1038/sj.mt.6300335

Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication. / Taylor, Jason; Vojtech, Lucia; Bahner, Ingrid; Kohn, Donald B.; Laer, Dorothee Von; Russell, David W.; Richard, Robert E.

In: Molecular Therapy, Vol. 16, No. 1, 01.2008, p. 46-51.

Research output: Contribution to journalArticle

Taylor, J, Vojtech, L, Bahner, I, Kohn, DB, Laer, DV, Russell, DW & Richard, RE 2008, 'Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication', Molecular Therapy, vol. 16, no. 1, pp. 46-51. https://doi.org/10.1038/sj.mt.6300335
Taylor, Jason ; Vojtech, Lucia ; Bahner, Ingrid ; Kohn, Donald B. ; Laer, Dorothee Von ; Russell, David W. ; Richard, Robert E. / Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication. In: Molecular Therapy. 2008 ; Vol. 16, No. 1. pp. 46-51.
@article{f70c060d9c7b46d3b01a76c18a4799c9,
title = "Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication",
abstract = "Gene therapy has the potential to control human immunodeficiency virus (HIV) in patients who do not respond to traditional antiviral therapy. In this study, we tested foamy virus (FV) vectors expressing three anti-HIV transgenes, both individually and in a combination vector. The transgenes tested in this study are RevM10, a dominant negative version of the viral rev protein, Sh1, a short hairpin RNA directed against a conserved overlapping sequence of tat and rev, and membrane-associated C46 (maC46), a membrane-attached peptide that blocks HIV cell entry. FV vectors efficiently transduce hematopoietic stem cells and, unlike lentivirus (LV) vectors, do not share viral proteins with HIV. The titers of the FV vectors described in this study were not affected by anti-HIV transgenes. On a direct comparison of FV vectors expressing the individual transgenes, entry inhibition using the maC46 transgene was found to be the most effective at blocking HIV replication. A clinically relevant FV vector expressing three anti-HIV transgenes effectively blocked HIV infection in primary macrophages derived from transduced, peripheral blood CD34-selected cells and in a cell line used for propagating HIV, CEM×174. These results suggest that there are potential benefits of using FV vectors in HIV gene therapy.",
author = "Jason Taylor and Lucia Vojtech and Ingrid Bahner and Kohn, {Donald B.} and Laer, {Dorothee Von} and Russell, {David W.} and Richard, {Robert E.}",
year = "2008",
month = "1",
doi = "10.1038/sj.mt.6300335",
language = "English (US)",
volume = "16",
pages = "46--51",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication

AU - Taylor, Jason

AU - Vojtech, Lucia

AU - Bahner, Ingrid

AU - Kohn, Donald B.

AU - Laer, Dorothee Von

AU - Russell, David W.

AU - Richard, Robert E.

PY - 2008/1

Y1 - 2008/1

N2 - Gene therapy has the potential to control human immunodeficiency virus (HIV) in patients who do not respond to traditional antiviral therapy. In this study, we tested foamy virus (FV) vectors expressing three anti-HIV transgenes, both individually and in a combination vector. The transgenes tested in this study are RevM10, a dominant negative version of the viral rev protein, Sh1, a short hairpin RNA directed against a conserved overlapping sequence of tat and rev, and membrane-associated C46 (maC46), a membrane-attached peptide that blocks HIV cell entry. FV vectors efficiently transduce hematopoietic stem cells and, unlike lentivirus (LV) vectors, do not share viral proteins with HIV. The titers of the FV vectors described in this study were not affected by anti-HIV transgenes. On a direct comparison of FV vectors expressing the individual transgenes, entry inhibition using the maC46 transgene was found to be the most effective at blocking HIV replication. A clinically relevant FV vector expressing three anti-HIV transgenes effectively blocked HIV infection in primary macrophages derived from transduced, peripheral blood CD34-selected cells and in a cell line used for propagating HIV, CEM×174. These results suggest that there are potential benefits of using FV vectors in HIV gene therapy.

AB - Gene therapy has the potential to control human immunodeficiency virus (HIV) in patients who do not respond to traditional antiviral therapy. In this study, we tested foamy virus (FV) vectors expressing three anti-HIV transgenes, both individually and in a combination vector. The transgenes tested in this study are RevM10, a dominant negative version of the viral rev protein, Sh1, a short hairpin RNA directed against a conserved overlapping sequence of tat and rev, and membrane-associated C46 (maC46), a membrane-attached peptide that blocks HIV cell entry. FV vectors efficiently transduce hematopoietic stem cells and, unlike lentivirus (LV) vectors, do not share viral proteins with HIV. The titers of the FV vectors described in this study were not affected by anti-HIV transgenes. On a direct comparison of FV vectors expressing the individual transgenes, entry inhibition using the maC46 transgene was found to be the most effective at blocking HIV replication. A clinically relevant FV vector expressing three anti-HIV transgenes effectively blocked HIV infection in primary macrophages derived from transduced, peripheral blood CD34-selected cells and in a cell line used for propagating HIV, CEM×174. These results suggest that there are potential benefits of using FV vectors in HIV gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=37549003223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549003223&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300335

DO - 10.1038/sj.mt.6300335

M3 - Article

C2 - 17955023

AN - SCOPUS:37549003223

VL - 16

SP - 46

EP - 51

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -